In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Glenmark gets rights to sell a generic form of Astellas' Locoid Lipocream in the US
03 Aug 2011
Astellas Pharma Inc. and its US marketing partner, specialty dermatology drug company Triax Pharmaceuticals LLC, have granted Glenmark Generics a royalty-bearing license to market a generic form of Locoid Lipocream (0.1% hydrocortisone butyrate). Glenmark, which has the right to sell its inflammation/dermatitis cortocosteroid in the US by the end of 2013, says it should be entitled to 180 days of exclusivity since it is the first generic firm to file an ANDA for the drug. Sales of Locoid Lipocream were $38mm for 2010. This is the second litigation settlement Glenmark has completed this month; Nycomed US Inc. also granted it a license to sell a generic form of atopic dermatitis therapy Cutivate.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?